From Sangamo, With a Lock on Genetic Switch Technology, Seeks to Morph Into Drugmaker:

lanphier

lanphier—

Edward Lanphier is CEO of Sangamo Biosciences

Underwriters and Partners

Xconomy Insight

Xconomy Insight · Special Report
How to Jump 5 Unforeseen Hurdles to Biotech Success – Startup Sourcebook
Insights, wisdom, and inspiration on what it takes

Sponsored · Whitepaper
How Healthy Are Your Market Access Programs?
A Guide to Performing Check-ups on Pharmaceutical Distribution & Patient Access Programs
Archbow Consulting

Sponsored · Whitepaper
The Importance of Early Key Opinion Leader Outreach in the Biologics & Biosimilars Marketplace
Acknowledging various stakeholder networks and regulatory environment variances is essential to uncover the right decision-makers in support of biologics or biosimilars
IBM Watson

Xconomy on Demand

We offer a number of ways to subscribe for free!